StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.85−0.04 (-4.46%)

Close on Nov 20, 2026Market cap $66.34MP/E –Yield –

Cardiff Oncology total assets

Total assets on the balance sheet at the end of each period.

Cardiff Oncology's total assets was $37.33M at Jun 30, 2026. For fiscal 2025 it was $61.88M, down 36.3% from the year before. Over ten years it grew -1.4% a year on average. The highest annual figure on record is $149.54M in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$61.88M-36.3%
FY2024Dec 31, 2024$97.19M+19.1%
FY2023Dec 31, 2023$81.64M-29.7%
FY2022Dec 31, 2022$116.19M-22.3%
FY2021Dec 31, 2021$149.54M+11.0%
FY2020Dec 31, 2020$134.73M+929.5%
FY2019Dec 31, 2019$13.09M-7.7%
FY2018Dec 31, 2018$14.17M+15.4%
FY2017Dec 31, 2017$12.28M-72.0%
FY2016Dec 31, 2016$43.95M-38.5%
FY2015Dec 31, 2015$71.45M+147.2%
FY2014Dec 31, 2014$28.90M+6.4%
FY2013Dec 31, 2013$27.16M+132.8%
FY2012Dec 31, 2012$11.67M+1022.4%
FY2011Dec 31, 2011$1.04M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$37.33M-50.7%
Q1 FY2026Mar 31, 2026$49.17M-42.0%
Q4 FY2025Dec 31, 2025$61.88M-36.3%
Q3 FY2025Sep 30, 2025$63.78M+1.4%
Q2 FY2025Jun 30, 2025$75.74M+14.7%
Q1 FY2025Mar 31, 2025$84.81M+14.5%
Q4 FY2024Dec 31, 2024$97.19M+19.1%
Q3 FY2024Sep 30, 2024$62.90M-28.9%
Q2 FY2024Jun 30, 2024$66.05M-32.2%
Q1 FY2024Mar 31, 2024$74.04M-30.5%
Q4 FY2023Dec 31, 2023$81.64M-29.7%
Q3 FY2023Sep 30, 2023$88.45M-28.5%
Q2 FY2023Jun 30, 2023$97.46M-25.8%
Q1 FY2023Mar 31, 2023$106.55M-23.5%
Q4 FY2022Dec 31, 2022$116.19M-22.3%
Q3 FY2022Sep 30, 2022$123.63M-12.5%
Q2 FY2022Jun 30, 2022$131.26M-8.7%
Q1 FY2022Mar 31, 2022$139.20M+7.4%
Q4 FY2021Dec 31, 2021$149.54M+11.0%
Q3 FY2021Sep 30, 2021$141.31M+258.2%
Q2 FY2021Jun 30, 2021$143.73M+377.1%
Q1 FY2021Mar 31, 2021$129.57M+996.6%
Q4 FY2020Dec 31, 2020$134.73M+929.5%
Q3 FY2020Sep 30, 2020$39.45M+230.9%
Q2 FY2020Jun 30, 2020$30.13M+117.3%
Q1 FY2020Mar 31, 2020$11.82M-18.7%
Q4 FY2019Dec 31, 2019$13.09M-7.7%
Q3 FY2019Sep 30, 2019$11.92M-33.5%
Q2 FY2019Jun 30, 2019$13.87M-36.3%
Q1 FY2019Mar 31, 2019$14.53M+39.6%
Q4 FY2018Dec 31, 2018$14.17M+15.4%
Q3 FY2018Sep 30, 2018$17.92M+46.7%
Q2 FY2018Jun 30, 2018$21.77M+73.3%
Q1 FY2018Mar 31, 2018$10.41M-69.3%
Q4 FY2017Dec 31, 2017$12.28M-72.0%
Q3 FY2017Sep 30, 2017$12.22M-76.9%
Q2 FY2017Jun 30, 2017$12.56M–
Q1 FY2017Mar 31, 2017$33.93M–
Q4 FY2016Dec 31, 2016$43.95M–
Q3 FY2016Sep 30, 2016$53.00M–

More Cardiff Oncology figures

See a number that looks wrong?